Friday, July 3, 2026

#pharmaceutical M&A

4 articles

Eli Lilly Crosses $20B in 2026 Acquisitions, Wagering AI Makes Bought Pipelines Cheaper Than Built Ones

Corporate Acquisitions

Eli Lilly Crosses $20B in 2026 Acquisitions, Wagering AI Makes Bought Pipelines Cheaper Than Built Ones

Salvado•May 31, 2026

Pharma Giants Reshape Portfolios Through M&A and Guidance Revisions as Sector Enters Active Optimization Phase

M&A and Corporate Finance

Pharma Giants Reshape Portfolios Through M&A and Guidance Revisions as Sector Enters Active Optimization Phase

ViaNews Editorial Team (Finance)•Feb 18, 2026

Pfizer Bets Big on Obesity: GLP-1 Market Entry Planned by 2028 After Metsera Deal

Corporate Strategy & M&A

Pfizer Bets Big on Obesity: GLP-1 Market Entry Planned by 2028 After Metsera Deal

ViaNews Editorial Team (Finance)•Feb 18, 2026

Precision Oncology Sector Reaches Inflection Point as Seven Companies Advance Toward FDA Submissions

Healthcare Investment

Precision Oncology Sector Reaches Inflection Point as Seven Companies Advance Toward FDA Submissions

ViaNews Editorial Team (Finance)•Feb 15, 2026